Navigation Links
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
Date:4/17/2008

a further increases our interest in exploring the combination of ANA598 with interferon and ribavirin as well as with other experimental direct antivirals."

About ANA598

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5b inhibitor, cellular activity in the hepatitis C replicon assay, oral bioavailability and early indicators of safety and tolerability. Anadys has recently completed IND enabling activities for ANA598 and pending allowance by the Food and Drug Administration, intends to initiate clinical studies of ANA598 in healthy volunteers in the second quarter of 2008. Following the healthy volunteer study, in the third quarter of 2008 Anadys plans to initiate a short-term Phase Ib study in patients infected with chronic HCV infection.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598, including future clinical trials and the belief that ANA598 has the broad potential utility to be used in combination with other anti-HCV agents, regardless of class, as well as the belief that ANA598 will be an active antiviral in HCV infected patients. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materiall
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ALISO VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... moved into expanded corporate offices in Aliso ... President, announced that due to the tremendous growth and ... critically needed. Sales of patented SnoreRx, the anti snore ... administrative offices. He said, "We are now in ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing cholangitis ... national team of researchers led by scientists at Mayo Clinic has ... liver disease, is not helpful for patients, according to a study ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO ...
... , ZURICH, Aug. 27 /PRNewswire/ -- ... of four phase III trials have been published in the prestigious peer-reviewed ... roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations ... COPD is an under-diagnosed progressive lung disease that may lead ...
Cached Medicine Technology:Researchers Find High-Dose Therapy for Liver Disease Not Effective 2Researchers Find High-Dose Therapy for Liver Disease Not Effective 3Researchers Find High-Dose Therapy for Liver Disease Not Effective 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... 2008 , ... Woburn, MA (PRWEB) July 30, 2008 -- Savings Bank ... for the Cure to promote awareness for ovarian cancer. The two ... Golf Tournament on August 4th, 2008 at the Weston Golf Club in ...
... July 30 GameTime employees were,honored to attend ... Give Kids the World Village. Give Kids the ... area that creates magical memories for,children with life-threatening ... its resort, along with donated attractions,tickets, meals and ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, July 30 /PRNewswire-FirstCall/ ... third quarter 2008 financial results,at 9:00 a.m. (Eastern Time) on Tuesday, ... President and CEO and Mrs. Ginette Gagne, CFO.,The Company will report ... on Tuesday, August 5., DATE: ...
... for breast cancer did not know that their odds of ... they undergo mastectomy or breast conserving surgery. Minority women were ... of their treatment decision, according to a study from the ... also less likely to know about relative survival rates even ...
... Warrior Project,(WWP), a non-profit organization that honors ... Ward, chairman and chief executive officer of,CSX ... contributed $1 million,toward education and rehabilitation., ... WWP,s new initiative called,Training Rehabilitation Advocacy Center ...
... DALLAS, July 30 Affiliated Computer Services,Inc. (NYSE: ... provide,electronic patient records capture for the City of New ... of the five-year contract, ACS will equip all New,Orleans, ... allows local EMS personnel to record complete patient data ...
Cached Medicine News:Health News:SBLI and Ovations for the Cure Team up to Raise Cancer Awareness 2Health News:GameTime Celebrates Opening of Give Kids the World Playground 2Health News:CryoCath to Hold Third Quarter 2008 Conference Call and Webcast 2Health News:Minorities less likely to know about breast cancer treatment options 2Health News:Minorities less likely to know about breast cancer treatment options 3Health News:Michael and Terry Ward Donate $1 Million to Wounded Warrior Project (WWP) 2Health News:ACS Awarded $4 Million Contract to Provide Electronic Patient Records for City of New Orleans EMS 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: